Bioheart Inc, a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announces an update on the phase I safety trial using adipose derived cells.
Approximately four years ago in April, 2010, Bioheart initiated a study using adipose derived stem cells (AdipoCell(TM)) in congestive heart failure patients. In collaboration with the Regenerative Medicine Institute of Tijuana, Mexico, five congestive heart failure patients were successfully treated in the initial pilot trial at Hospital Angeles Tijuana. Patients underwent a mini-lipoaspiration procedure where 60ccs of fat were removed.
This fat was processed to obtain the stromal vascular fraction (SVF) which
Three teams of USC stem cell researchers have won a coveted prize — the opportunity to test 3,000 drug candidates or chemicals for the potential to help patients. Two teams will focus their efforts on cancer; the third will search for ways to accelerate the healing of large bone fractures.
The free screens will take place at the Choi Family Therapeutic Screening Facility, part of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC. Andrew McMahon, director of the stem cell research center, is sponsoring the bone repair project, and Stephen Gruber, director of
One in 10 adults in the U.S. — more than 20 million people — are suffering from some degree of chronic kidney disease. Kidney transplants offer a hope for cure, but thousands of patients die each year due to a shortage of donor organs. Even patients who are lucky enough to receive transplants run the risk of their immune systems rejecting the donor kidneys, and they have to take immunosuppressive drugs with serious side effects for the rest of their lives.
Vito Campese, professor and chair of the Keck School of Medicine of USC’s nephrology division, underscores the need to
Veterinarians in Wichita conducted the first phase of a stem cell trial today in Wichita. Their goal is to treat laminitis, a disease in horses hoofs. They will do this using stem cells taken from the horses using liposuction. Laminitis is painful and even crippling for horses.
“Those horses usually digress over time to the point where they finally lose their life,” Dr. Preston Hickman said.
The trial is 90 days. The ten horses participating will have 3 stem cell injections over the three months.
Mouse severely disabled by a condition similar to multiple sclerosis (MS) could walk less than two weeks following treatment with human stem cells.
When scientists transplanted human stem cells into MS mice, they expected no benefit from the treatment. They thought the cells would be rejected, much like rejection of an organ transplant.
Instead, the experiment yielded spectacular results.
Within a short period of time, 10 to 14 days, the mice could walk and run. Six months later, they showed no signs of slowing down.